CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,230,845
- in 7 filings, $1.6M under 10b5-1 plans
Net −$2,230,845. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 37 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +3,250 | $2.48 | $8K | 26,250 |
| 2025-03-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −3,250 | $21.33 | $69K | 23,000 |
| 2025-03-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −3,250 | 128,556 | ||
| 2025-03-24 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +1,000 | $2.48 | $2K | 24,000 |
| 2025-03-24 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −1,000 | $22.50 | $23K | 23,000 |
| 2025-03-24 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −1,000 | 131,806 | ||
| 2025-03-19 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −12,500 | $20.61 | $258K | 1,002,688 |
| 2025-03-17 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −12,500 | $20.83 | $260K | 990,392 |
| 2025-03-07 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −6,667 | $21.44 | $143K | 323,310 |
| 2025-03-04 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise | +10,000 | $2.48 | $25K | 23,000 |
| 2025-03-04 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) | −10,000 | 132,806 | ||
| 2025-02-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +3,250 | $2.48 | $8K | 16,250 |
| 2025-02-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −3,250 | $20.41 | $66K | 13,000 |
| 2025-02-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −3,250 | 142,806 | ||
| 2025-02-07 | Patel Anish CHIEF OPERATING OFFICER | Sale | −6,667 | $21.93 | $146K | 329,977 |
| 2025-02-06 | Phillips Andrew John Director | Grant or award · Stock Option (right to buy) | +20,491 | 20,491 | ||
| 2025-02-06 | Kunkel Lori Anne Director | Grant or award · Stock Option (right to buy) | +15,368 | 15,368 | ||
| 2025-02-06 | Heyman Richard A. Director | Grant or award · Stock Option (right to buy) | +23,014 | 23,014 | ||
| 2025-02-06 | Gupta Rishi Director | Grant or award · Stock Option (right to buy) | +20,491 | 20,491 | ||
| 2025-02-06 | Derynck Mika K Director | Grant or award · Stock Option (right to buy) | +20,491 | 20,491 |
Page 12 of 37 · 724 trades